The DNA methylome is a rich source of information about human disease. Adela’s genome-wide methylome enrichment platform uniquely captures information efficiently from the entire methylome.
Adela’s technology distinguishes the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially targets those regions for sequencing.
In addition, Adela’s technology does not require bisulfite conversion, which is a chemical treatment that causes loss of valuable genomic material and information.
Adela's technology leverages machine learning to detect and classify underlying disease, including tissue of origin and histologic subtype.
Toronto · San Francisco
